Impact of Sexual Dysfunction in Patients in Remission With Major Depressive Disorder

November 29, 2017

This poster was presented at the 30th annual  Psych Congress, held Sept. 16-19, 2017, in New Orleans, Louisiana.

Objective: To evaluate and compare the clinical burden of depression in patients in remission from major depressive disorder at 2 months, with vs without sexual dysfunction.

Methods: In the Prospective Epidemiological Research on Functioning Outcomes Related to Major depressive disorder (PERFORM) study, patients in remission (Clinical Global Impressions-Severity score ≤3) with Arizona Sexual Experience Scale (ASEX) data at month 2 were identified. Patients with sexual dysfunction were those with ASEX total score ≥19 or ≥1 ASEX item ≥5 or ≥3 ASEX items ≥4.

Results: Of the 132 patients in remission at month 2, 92 (69.7%) had sexual dysfunction. At month 2, mean ± SD total scores on Patient Health Questionnaire-9 (PHQ-9; 10.8±6.0 vs 6.5±4.4), Montgomery-Åsberg Depression Rating Scale (MADRS; 10.5±6.9 vs 5.4±6.2), Sheehan Disability Scale (SDS; 12.8±7.1 vs 9.1±6.6), and Perceived Deficit Questionnaire-5 (PDQ-5; 9.5±4.6 vs 7.3±4.3) were numerically higher in patients with vs without sexual dysfunction. Mean ± SD scores on the mental (34.9±10.8 vs 40.0±10.4) and physical health (45.3±11.3 vs 51.7±6.9) components of the 12-Item Short-Form Survey were numerically lower in patients with vs without sexual dysfunction at month 2. Although both groups experienced further improvements in these indicators of function and disease severity at month 6, scores remained worse in patients with sexual dysfunction.

Conclusions: More than two-thirds of patients in remission at month 2 in the PERFORM study had sexual dysfunction suggestive of worse prognoses regarding depression severity, functioning, quality of life and cognitive dysfunction outcomes than patients without sexual dysfunction.

Authors: 
Maëlys Touya, MSc, PharmD; Françoise Diamand, MSc; Delphine Saragoussi, MD, MScPH; Clément François, PhD; Christophe Lançon, MD, PhD
Sponsoring Organization: 
Lundbeck LLC
Year: 
2017
Tracks: 
Mood Disorders